About Ancora Pharmaceuticals
Ancora Pharmaceuticals is a company based in Milton Keynes (United Kingdom) founded in 2002 was acquired by Corden Pharma in October 2013. Ancora Pharmaceuticals has raised $800 thousand across 3 funding rounds from investors including HHS and Corden Pharma. Ancora Pharmaceuticals operates in a competitive market with competitors including Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
- Headquarter Milton Keynes, United Kingdom
- SectorsHealthcare
- Phone•••• ••••
- Website ancorapharma.com
- Acquired by Corden Pharma (Oct 2013)
- Legal Name Ancora Pharmaceuticals Inc
- Total Equity Funding$800K (USD)
in 3 rounds
- Latest Funding Round$800K (USD), Seed
Nov 2009
- InvestorsHHS
& 1 more
- Acquired byCorden Pharma
(Oct 2013)
Funding Insights of Ancora Pharmaceuticals
Ancora Pharmaceuticals has successfully raised a total of $800K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $800 thousand completed in November 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $800,000
- Total Rounds 3
- Last Round Seed — $800,000
- First Round $530,977
(Apr 2009)
- Investors Count 1
All 3 funding rounds of Ancora Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Ancora Pharmaceuticals
Ancora Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Corden Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
CDMO offering its services for small molecules, peptides, lipids and carbohydrates | 2006 | cordenpharma.com | Plankstadt, Germany |
Investor details for Ancora Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ancora Pharmaceuticals
4 dated milestones of Ancora Pharmaceuticals across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Ancora Pharmaceuticals is founded.
- Funding First funding round of $531K.
- Funding Latest funding round, Seed, of $800K.
- Exit Acquired by Corden Pharma.
Competitors of Ancora Pharmaceuticals
Ancora Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| aridispharma.com | 2005 | San Jose, United States | $42.11M | 34 | Provider of human monoclonal antibodies against infectious diseases | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| maatpharma.com | 2014 | Lyon, France | $42.3M | – | Microbiome therapies are developed for treating intestinal dysbiosis diseases. | |
| briacell.com | 2004 | Beverly Hills, United States | – | 16 | Developer of immunotherapies for the treatment of cancer | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI |
Detailed competitors of Ancora Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Ancora Pharmaceuticals
10 companies that operate in the same segment as Ancora Pharmaceuticals (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ancora Pharmaceuticals
Ancora Pharmaceuticals was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Ancora Pharmaceuticals is headquartered in Milton Keynes, United Kingdom.
Ancora Pharmaceuticals is a funded company, having raised a total of $800K across 3 funding rounds to date. The company's 1st funding round was a Grant of $530.98K, raised on Apr 2009.
Ancora Pharmaceuticals was founded in 2002 and is located in Milton Keynes, United Kingdom. Focus is placed on the biotechnology sector, where vaccines targeting hospital-acquired infections such as those from Staphylococcus, Enterococcus, Candida, and Moraxella are developed. Lead candidates remain in preclinical development. Efforts also extend to vaccines addressing community-acquired infections and potential bioterrorism threats.
Ancora Pharmaceuticals's top competitors include Imvax, Aridis Pharma and Insmed.
Ancora Pharmaceuticals has 2 investors. Key investors include HHS, and Corden Pharma.
Ancora Pharmaceuticals operates through Ancora Pharmaceuticals Inc.
Yes. Ancora Pharmaceuticals was acquired by Corden Pharma in October 2013.